The factors that influence carbamazepine (CBZ) serum concentrations and levehdose ratios were evaluated retrospectively on 83 consecutive routine CBZ determinations from chronically treated epileptic patients. The total levehdose ratio was lower when the drug was given in combination with phenytoin or with phenytoin plus other anti‐epileptic drugs (AED) than when CBZ was given alone. The free levehdose ratio was also decreased during concomitant treatment with phenytoin. In spite of alterations to both levehdose ratios, the free fraction of CBZ was unaltered when in combination with other AEDs. There were statistically significant correlations between the CBZ dose (mg/kg/day) and the serum levels:total (r= 0.372, P< 0.001) and free (r= 0.335, P< 0.005). However, the wide scatter in the CBZ serum levels at each given dose were such that the relationships had no predictive values. Stepwise multivariate regression analysis (MVR) was also performed. A comparison of the normalized regression coefficients indicated that the CBZ dose, PHT dose, the time elapsed from the previous dose, the albumin concentration and the triglyceride levels were important factors which influence the CBZ total serum level. Similar analysis for the CBZ free serum level, gave a multiple correlation coefficient of 0.838, which indicates that 70.3% of the variance was explained by nine independent variables. The major factors that significantly affected the free serum level of CBZ were CBZ dose, PHT dose, the time elapsed from the previous dose and the triglyceride and albumin levels. Our observations indicate that it may be possible to predict reliably the CBZ serum concentrations for individual patients before institution of CBZ therapy.
|Number of pages||13|
|Journal||Journal of Clinical Pharmacy and Therapeutics|
|Publication status||Published - Oct 1990|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)